Eylul joined NEA in 2015 as an associate and focuses on healthcare investments. She is a board observer for DOTS Technology Corp and Eargo. She is also actively involved with NEA’s investments in Cleave Biosciences, Intrinsic Therapeutics, Moximed, Neotract, Setpoint and Willow. Prior to joining NEA, Eylul was a member of Morgan Stanley’s Healthcare Investment Banking and Equity Capital Markets teams where she was engaged in M&A and equity transactions for more than 30 unique companies in the healthcare space, including NEA portfolio companies such as Nevro and Tesaro.
Eylul graduated from Columbia University, with a B.A. in Economics and Mathematics.